Literature DB >> 30014156

Bisphosphonate use after clinical fracture and risk of new fracture: response to comments by Wu et al.

J Bergman1, A Nordström2,3, P Nordström4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30014156     DOI： 10.1007/s00198-018-4615-5

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  11 in total

1.  Reporting statistical information in medical journal articles.

Authors:  Peter Cummings; Frederick P Rivara
Journal:  Arch Pediatr Adolesc Med       Date:  2003-04

2.  Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women.

Authors:  Laura Y Park-Wyllie; Muhammad M Mamdani; David N Juurlink; Gillian A Hawker; Nadia Gunraj; Peter C Austin; Daniel B Whelan; Peter J Weiler; Andreas Laupacis
Journal:  JAMA       Date:  2011-02-23       Impact factor: 56.272

3.  Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients-a nationwide register-based open cohort study.

Authors:  L Bondo; P Eiken; B Abrahamsen
Journal:  Osteoporos Int       Date:  2012-05-26       Impact factor: 4.507

4.  Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study.

Authors:  W Brozek; B Reichardt; J Zwerina; H P Dimai; K Klaushofer; E Zwettler
Journal:  Osteoporos Int       Date:  2015-11-17       Impact factor: 4.507

Review 5.  Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2013-10-01       Impact factor: 6.741

6.  Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study.

Authors:  Bo Abrahamsen; Pia Eiken; Richard Eastell
Journal:  J Bone Miner Res       Date:  2009-06       Impact factor: 6.741

Review 7.  Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review.

Authors:  Carolyn J Crandall; Sydne J Newberry; Allison Diamant; Yee-Wei Lim; Walid F Gellad; Marika J Booth; Aneesa Motala; Paul G Shekelle
Journal:  Ann Intern Med       Date:  2014-11-18       Impact factor: 25.391

8.  Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis.

Authors:  Catherine MacLean; Sydne Newberry; Margaret Maglione; Maureen McMahon; Veena Ranganath; Marika Suttorp; Walter Mojica; Martha Timmer; Alicia Alexander; Melissa McNamara; Sheetal B Desai; Annie Zhou; Susan Chen; Jason Carter; Carlo Tringale; Di Valentine; Breanne Johnsen; Jennifer Grossman
Journal:  Ann Intern Med       Date:  2007-12-17       Impact factor: 25.391

9.  Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study.

Authors:  Bo Abrahamsen; Pia Eiken; Daniel Prieto-Alhambra; Richard Eastell
Journal:  BMJ       Date:  2016-06-28

10.  Bisphosphonate use after clinical fracture and risk of new fracture.

Authors:  J Bergman; A Nordström; P Nordström
Journal:  Osteoporos Int       Date:  2018-02-03       Impact factor: 4.507
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.